Striatal Isolated from *Cyathus striatus* Extracts Induces Apoptosis in Human Pancreatic Cancer Cells

Fuad Fares 1,*, Soliman Khatib 2,3, Jacob Vaya 2, Lital Sharvit 1, Einav Eizenberg 1 and Solomon Wasser 4

1 Department of Human Biology, Faculty of Natural Sciences, University of Haifa, Haifa 3498838, Israel; lsharvit@univ.haifa.ac.il (L.S.); einave.seidner@gmail.com (E.E.)
2 Laboratory of Natural Compounds and Analytical Chemistry, MIGAL Galilee Research Institute, Kiryat Shmona 11016, Israel; solimankh@migal.org.il (S.K.); vaya@migal.org.il (J.V.)
3 Tel-Hai College, Tel-Hai 1220800, Israel
4 Institute of Evolution and Department of Evolutionary and Environmental Biology, Faculty of Natural Sciences, University of Haifa, Haifa 3498838, Israel; spwasser@research.haifa.ac.il

* Correspondence: ffares@univ.haifa.ac.il or ffares@sci.haifa.ac.il; Tel.: +972-4-8288781; Fax: +972-4-8288763

Abstract: The aim of the present study was to identify the structure of active compounds in *Cyathus striatus* that previously demonstrated anti-pancreatic cancer activity. The active compounds were purified from a crude extract by a series of RP-18 preparative chromatography using homemade octadecyl silica gel column. HPLC injection of the crude extract revealed a chromatogram with three main peaks with retention times (RT) 15.6, 18.2, and 22.5 min. Each fraction that exhibited promising activity in vitro was further separated using various available chromatographic techniques. The purified compound with the ultimate anti-cancer activity appeared at RT of 15.8 in the HPLC chromatogram with more than 90% purity. The main peak at the mass spectra appeared at $m/z = 446.2304$ with the calculated molecular formula of $C_{25}H_{34}O_7$. One- and two-dimensional NMR analyses indicated that the structure of the active molecule (peak 15.8 min in HPLC) was identified as striatal C. Exposure of human pancreatic cancer cells to purified striatal C resulted in induction of apoptosis. Further studies are needed in order to develop a method for the synthesis of striatal in order to use it in clinical studies for treatment of cancer.

Keywords: medicinal mushroom; *Cyathus striatus*; striatal; pancreatic cancer; apoptosis

1. Introduction

Natural products have been the most important source of drugs in history [1]. Many edible mushrooms were used in traditional folk medicine while others are used only for their medicinal properties [2–5]. Medicinal mushrooms were used as natural compounds to modulate immune responses and possess anti-cancer, anti-microbial, and anti-oxidant properties [6,7]. In addition, it was reported that oyster mushrooms, commonly known as *Pleurotus ostreatus*, induced apoptosis in human colon cancer cells (HCT-116) in a dose-dependent manner (12.5 to 200 µg/mL) [8]. Moreover, it was reported for the first time that the oyster mushroom *Pleurotus florida* mediated trimetallic nanoparticle synthesis via a rapid, simple, environmentally friendly, economical, and feasible method [9]. Mushrooms are described as a rich source of bioactive compounds and contain primary and secondary metabolites, where the secondary metabolites exhibit medicinal properties [10]. Many pharmaceutical substances with potent and unique properties have been extracted from mushrooms and anti-cancer remedies were prepared from these extracts, such as the following polysaccharides: lentinan, krestin, and schizophyllan [11]. Higher Basidiomycetes mushrooms (HBMs) represent a major and still largely unexploited source of new pharmaceutical products. It was suggested that HBMs act as immunomodulators or biological response modifiers (BRMs). This advantage is one of the reasons why they are currently used as adjuncts to cancer treatment in many countries [12]. Fungal
metabolites have been gaining scientific interest for their medicinal properties. Studies on medicinal mushrooms proved their potential not only as dietary supplements and immunomodulators [13,14], but also as modulators of various cellular responses [15]. Low-molecular-weight (LMW) substances with fungal origins can penetrate cell membranes and interfere, in particular, with cellular pathways linked to processes such as inflammation, carcinogenesis, cell differentiation survival, and metastasis. Characteristic changes such as deregulation of cell cycle machinery, self-sufficiency in growth signals, insensitivity to growth inhibitory signals, evasion of apoptosis, tissue invasion, metastasis, and sustained angiogenesis are hallmarks of majority of cancers and can be found in pancreatic ductal adenocarcinoma (PDAC) [16–19].

*Cyathus striatus* (CS) is a higher Basidiomycetes mushroom of the family Nidulariaceae. It has widespread distribution throughout temperate regions of the world. CS is a rich source of bioactive chemical compounds. It was reported that CS produces indole substances, complexes of diterpenoid antibiotic compounds, and cyathins [20]. The indole substances, which were later named striatins (A, B, and C), have antibiotic activity against imperfect fungi and various Gram-positive and Gram-negative bacteria [21]. However, most bioactive substances isolated from mushrooms are high molecular weights, (HMWs) such as polysaccharides. Our interest is in LMW compounds that are capable of exhibiting anti-tumor activity. Previously, we found that ethyl acetate extracts from CS media induced apoptosis in human pancreatic cancer cells through extrinsic and intrinsic apoptotic pathways [22,23]. In addition, gene expression analysis revealed the involvement of mitogen-activated protein kinase (MAPK) and P53 signaling pathways and pointed toward endoplasmic reticulum stress-induced apoptosis. Moreover, CS extracts significantly inhibited tumour growth in vivo using animal models [23]. Thus, we have focused on the search for novel LMW compounds in CS extracts that induce apoptosis in human pancreatic cancer cells, and therefore, might be useful in the search of new therapies for pancreatic cancer.

2. Materials and Methods

2.1. Extract Production

The mycelium of the CS mushroom was grown first on solid medium and then it was transferred onto submerged conditions, as described before [24]. The specific strain was grown in submerged conditions for biomass production for a period of 10 days, long enough to reach the growth stage of secondary metabolite production. The growing media of the mushroom, culture liquid (CL), was extracted with ethyl acetate (EAC) in ratio of 1000 mL (CL):500 mL (EAC) [25]. The dried extract was diluted with 99.9% dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO, USA) to reach a concentration of 50 mg/mL and it was kept at −20 °C until use.

2.2. Isolation and Structure Elucidation of the Bioactive Compound

The active compounds were purified from the extract (0.5 g of crude extract) by a series of RP-18 preparative chromatography using homemade reverse-phase octadecyl silica gel column. The solvents used to eluate the extract fractions were (A)—double distilled water (DDW) and (B)—acetonitrile (ACN). The chromatography started with 0% of solvent B, then it increased by 5% every 10 min to 100% B, and it was kept at 100% B for another 30 min. Flow rate was 5 mL/min to obtain 5 mg of the most active compound which appeared at 16 min in the HPLC chromatogram.

2.3. HPLC Analysis

The chromatographed fractions were analyzed by injecting 20 µL of the fraction solution dissolved in methanol (2 mg mL⁻¹) into a UHPLC connected to a photodiode array detector (Dionex Ultimate 3000) with a reverse-phase column (Phenomenex RP-18, 150 4.0 mm, 3 µm). The mobile phase consisted of (A) DDW with 0.1% formic acid and (B) acetonitrile containing 0.1% formic acid, run at a gradient starting from 40% B, then
increased to 90% B for 22 min, and kept at 90% B for another 8 min, at a flow rate of 1 mL min\(^{-1}\).

2.4. LC–MS Analysis

LC–MS analysis was performed with an electrospray ionization (Dual AJS ESI+) source connected to a UHD accurate-mass Q-TOF LC–MS 6540A (Agilent Technologies). The ESI capillary voltage was set to 4000 V, the fragmenter to 150 V, gas temperature to 300 °C, gas flow to 8 mL/min, and nebulizer to 35 psi. The mass spectra (m/z 100–1000) were acquired in positive-ion mode.

2.5. NMR Analysis

The isolated compound was dissolved in deuterated chloroform (CD\(_3\)Cl) and NMR spectra were recorded at room temperature with AV-III 600 Bruker spectrometer. The \(^{13}\)C-NMR spectra were recorded using zgig and dept-135; 2D-NMR methods included COSY, HSQC, and HMBC.

2.6. Cell Culture

The human pancreatic cancer cell lines—HPAF-II, well differentiated, and PL45, poorly differentiated (ATCC, Rockville, MD, USA)—were maintained in MEM-EAGLE and DMEM media, respectively, supplemented with 1% L-glutamine, 10% fetal calf serum (FCS), and 1% PenStrep (penicillin + streptomycin) (Biological industries, Kibbutz Beit-Haemek, Israel). The HPAF-II cell line was supplemented with an additional 1% sodium pyruvate, and the PL45 cell line was supplemented with an additional 1% L-glutamine. Cells were grown in a humidified incubator at 37 °C with 5% CO\(_2\) in air and were fed twice a week with fresh media.

2.7. Cell Proliferation

Evaluation of the fungal extract effect on cell line viability was performed using an XTT assay (Biological Industries, Kibbutz Beit-Haemek, Israel). HPAF-II and PL45 cells (10\(^4\)) were seeded in 100 µL of medium using 96-well plates. After 24 h, the fungal extract was added (1, 2.5, 5, 7.5, 10, 15, and 50 µg/mL) for 4, 8, 12, 24, 48, and 72 h, respectively. After this, viability level was determined according to the manufacturer’s instructions using an Elisa reader (BioTek) at 450 nm and subtracted from the reference absorbance at 620 nm. Survival was compared to that of vehicle-treated control cells. The experiments were repeated 2–5 times independently and conducted in at least 3 replicates. Data was presented as the average proliferation percentage of the respective control.

2.8. Effect of CS Extract on Lactate Dehydrogenase (LDH) Release

LDH is a cytoplasmic enzyme that catalyzes the oxidation of L-lactate to pyruvate with NAD\(^+\) as a hydrogen acceptor—the final step in the metabolic chain of anaerobic glycolysis. The extracellular appearance of LDH serves as a marker for tissue lysis since cell damage, such as necrosis, causes a rise in LDH in the cells’ medium [21,26]. In order to exclude the possibility for cytotoxic effects of the extract on the cell lines, LDH leakage into the medium was measured in aliquots of the extracellular fluid of each sample using an LDH Cytotoxicity Detection Kit (Roche Diagnostics, Mannheim, Germany).

2.9. Cell Cycle Analysis

A total of 10\(^6\) HPAF-II and PL45 cells were treated with selected doses of the CS extract or with the purified fractions for a treatment period that was determined according to the XTT results. Then, the cells were trypsinized and collected with the growth medium, centrifuged, washed with PBS, and fixed with 70% ethanol for one hour. This was followed by incubation with 0.1% NP-40 for 5 min in 4 °C followed by incubation on ice with 100 µg/mL RNase for 30 min. Finally, 50 µg/mL PI was added for 20 min. Cell cycle phase distribution was determined by Fluorescence Activated Cell Sorter (FACS) flow cytometry.
2.10. Apoptosis

Apoptotic cells were detected by several methods as follows.

2.10.1. Annexin-V

Cell apoptosis was measured using Annexin V-FITC Apoptosis Detection Kit (MBL, Woburn, MA, USA). Briefly, $10^6$ cells were seeded in T-25 flasks. On the next day, HPAF-II and PL45 cells were treated with selected doses of the CS extract or fractions for 4 h. At the end of treatment time, cells were trypsinized and collected with the growth medium, centrifuged, washed with PBS, and $2 \times 10^5$ cells were counted and collected for the analysis. The cells were resuspended in 85 µL of 1X binding buffer; 10 µL of Annexin V-FITC and 5 µL of propidium iodide were added. Cells were incubated for 15 min at room temperature in the dark prior to analysis. Apoptosis cells were determined using a BD Facscalibur flow cytometer (Becton Dickinson, USA).

2.10.2. TUNEL Assay

Cell morphology was examined using TUNEL (In Situ Cell Death Detection Kit, Roche) and DAPI staining. The cells were washed twice with PBS and fixed for 60 min. Subsequently, the cells were incubated with a TUNEL reaction mixture that contained TdT and fluorescein-dUTP. During this incubation period, TdT catalyzes the addition of fluorescein-dUTP at the free 3′-OH groups in single- and double-stranded DNA. After washing, the label incorporated at the damaged sites of the DNA is visualized by fluorescence microscopy. DAPI stain was added on top of TUNEL-treated cells.

2.11. Statistical Analysis

All experiments were repeated at least three times (unless indicated otherwise). All data were expressed as a mean ± standard error (SE) and the statistical differences between groups were evaluated using Student’s t-test for comparison between two groups or ANOVA test (or their non-parametric counterparts) for comparison between multiple groups. A $p < 0.05$ was considered statistically significant and SPSS software was used for the calculation of differences.

3. Results

3.1. Isolation and Identification of the Active Compound Structure

Bioassay-guided fractionation approach led to the isolation of the desired active compounds. HPLC injection of the crude extract revealed a chromatogram with three main peaks with retention times (RT) 15.6, 18.2, and 22.5 min (Figure S1A, in Supplementary Materials). Purification of the extract by a series of chromatographic fractionations using RP-18 preparative column obtained several fractions. Each fraction that exhibited promising activity in vitro was further separated using various available chromatographic techniques. All isolated fractions were examined in vitro using an XTT assay for evaluation of biological activity.

The purified compound with the ultimate anti-cancer activity appeared at RT of 15.8 min in the HPLC chromatogram with more than 90% purity (Figure S1B, in Supplementary Materials). LC–MS of the compound shows two peaks. The main peak at the mass spectra appeared at $m/z = 447.2382$ (M + H$^+$) with the calculated molecular formula of $C_{25}H_{34}O_7$, and the second peak appeared at $m/z = 429.2275$ (M + H$^+$H$_2$O) with the calculated molecular formula of $C_{25}H_{32}O_6$ (elimination of water, H$_2$O) (Figure 1). By using one- and two-dimensional NMR analyses ($^1$H-NMR, $^{13}$C-NMR, $^{13}$C-DEPT135, COSY, HSQC, and HMBF, Figures S2–S7 in Supplementary Materials), the structure of the active molecule (peak 15.8 min in HPLC) was elucidated as striatal C (Figure 2 and Table 1). $^{13}$C-NMR spectra of the active compound show twenty-five carbons; two of
them are carbonyls (C14 and C3′), four carbons with double bonds (C3, C4, C11, and C12), and one acetal carbon (C1′) (Table 1). 13C-DEPT135 analysis showed the presence of four methyl groups (CH3), five methylene (CH2) groups, nine methine groups (CH), and seven quaternary groups (Table 1). According to the LC–MS and NMR spectroscopic data, the active compound (peak 15.8 min in HPLC) was identified as striatal C (Table 1, and Figure 2). The peak at 18.2 min was elucidated as striatal D (data not shown).

Table 1. Assignment of the signals in the one- and two-dimensional NMR spectra of the isolated active compound (striatal C). The 1H- and 13C-NMR spectra were measured at 600 MHz and coupling constants are in Hz.

| Carbon Number | 13C-NMR (ppm) | 1H NMR Shifts (ppm) and Multiplicity | Number of Protons | 13C-NMR DEPT135 | Adjacent 1H-COSY (ppm) | HMBC Correlations |
|---------------|---------------|--------------------------------------|-------------------|-----------------|-----------------------|------------------|
| C1            | 39.22         | 1.72t                                | 2                 | CH2             | 2.3                   | C3, C4           |
| C2            | 28.85         | 2.31t                                | 2                 | CH2             | 1.72                  | C3, C4           |
| C3            | 140.16        |                                       | -                 | -               | -                     |                  |
| C4            | 134.94        |                                       | -                 | -               | -                     |                  |
| C5            | 46.02         | 2.17                                 | 1                 | CH              | -                     | C3, C4, C6, C7, C11, C16 |
| C6            | 42.15         |                                       | -                 | -               | -                     |                  |
| C7            | 28.78         | 1.58                                 | 2                 | CH2             | C6, C9                |                  |
| C8            | 36.60         | 1.57                                 | 2                 | CH2             | C4, C6, C9            |                  |
| C9            | 49.17         |                                       | -                 | -               | -                     |                  |
| C10           | 68.77         | 4.96d                                | 1                 | CH              | 6.90                  | C4, C5, C6, C11, C12, |
| C11           | 154.64        | 6.90dd                               | 1                 | CH              | 4.96                  | C15, C6          |
| C12           | 143.12        |                                       | -                 | -               | -                     |                  |
| C13           | 45.88         | 3.27, 3.28d                          | 1                 | CH              | 4.5                   | C6, C11, C12, C14, C2′, C3′ |
| C14           | 86.57         | 4.52, 4.54d                          | 1                 | CH              | 3.27                  | C5, C7, C12, C16 |
| C15           | 197.01        | 9.3s                                 | 1                 | CH              | -                     | C12, C13         |
| C16           | 21.11         | 1.22s                                | 3                 | CH3             | -                     | C5, C6, C7, C14 |
| C17           | 23.88         | 0.96s                                | 3                 | CH3             | -                     | C1, C4, C8, C9, |
| C18           | 26.35         | 3.0q                                 | 1                 | CH              | 0.98, 1.04            | C3, C2, C19, C20 |
| C19           | 21.87         | 0.98d                                | 3                 | CH3             | 3.0                   | C3, C18, C20    |
| C20           | 21.62         | 1.04d                                | 3                 | CH3             | 3.0                   | C3, C18, C19    |
| C1′           | 108.02        | 5.29s                                | 1                 | CH              | -                     | C14, C5′, C3′    |
| C2′           | 83.50         |                                       | 0                 | 0               | -                     |                  |
| C3′           | 204.30        |                                       | 0                 | -               | -                     |                  |
| C4′           | 75.00         | 4.03                                 | 1                 | CH              | 3.7                   | C4′, C3′         |
| C5′           | 68.62         | 4.30, 4.28, 3.80, 3.78dd             | 2                 | CH2             | 4.03                  |                  |

*: This column represents 1H NMR chemical shifts and multiplicity; the 1H NMR shifts correlated with the 13C NMR chemical shifts using HSQC 2D-NMR spectral analysis. #: this column represents the number of protons obtained from peak integration from the 1H NMR spectra.
The purified compound with the ultimate anti-cancer activity appeared at RT of 15.8 min in the HPLC chromatogram with more than 90% purity (Figure S1B, in Supplementary Materials). LC–MS of the compound shows two peaks. The main peak at the mass spectra appeared at \( m/z = 447.2382 \) (M + H +) with the calculated molecular formula of \( C_{25}H_{34}O_{7} \), and the second peak appeared at \( m/z = 429.2275 \) (M + H + - H2O) with the calculated molecular formula of \( C_{25}H_{32}O_{6} \) (elimination of water, H2O) (Figure 1). By using one- and two-dimensional NMR analyses (\(^1\)H-NMR, \(^{13}\)C-NMR, \(^{13}\)C-DEPT135, COSY, HSQC, and HMBC, Figures S2–S7 in Supplementary Materials), the structure of the active molecule (peak 15.8 min in HPLC) was elucidated as striatal C (Figure 2 and Table 1). \(^{13}\)C-NMR spectra of the active compound show twenty-five carbons; two of them are carbonyls (C14 and C3′), four carbons with double bonds (C3, C4, C11, and C12), and one acetal carbon (C1′) (Table 1). \(^{13}\)C-DEPT135 analysis showed the presence of four methyl groups (CH3), five methylene (CH2) groups, nine methine groups (CH), and seven quaternary groups (Table 1). According to the LC–MS and NMR spectroscopic data, the active compound (peak 15.8 min in HPLC) was identified as striatal C (Table 1, and Figure 2). The peak at 18.2 min was elucidated as striatal D (data not shown).

**Figure 1.** Mass spectra of the purified compound using QTOF LC–MS with ESI+ scan mode.

**Figure 2.** Structure of striatal C at 15.8 min and striatal D at 18.2 min in the HPLC chromatogram.

3.2. The Effect of the Isolated Active Compound on Cell Viability

The effect of the purified fraction, RT16, which contains striatal C was examined on viability of the human pancreatic cancer cell lines HPAF-II (Figure 3A) and PL45 (Figure 3B) in vitro. The cells were treated with different doses, 2.5–10 \( \mu \)g/mL, of RT16 and crude extract for 8, 12, and 24 h. The results indicated that RT16 significantly reduced cell viability of HPAF-II and PL45 in a dose-dependent manner, as well as the crude extract. Interestingly, the maximal effect was reached after 8h of treatment. Exposure of the cells to 10 \( \mu \)g/mL RT16 fraction for 8 h inhibited growth by 85% and 75% of HPAF-II and PL45 cells, respectively (\( p < 0.001 \)). Whereas treatment of the cells with the CS extract (10 \( \mu \)g/mL) decreased viability by \( \sim 60\% \) (\( p < 0.001 \)).
In order to exclude the possibility for cytotoxic effects of RT16 on the cells, LDH leakage into the medium was measured following treatment with different concentrations of RT16 for 24 h. The results indicated that the effective doses of RT16, 2.5, 5 and 10 μg/mL, and 200 μM etoposide, a chemotherapy medication, have no significant effect on the release of LDH from the cells into the media. However, all treatments were found significantly different from the positive control (treatment of the cells with 2% Triton X-100) as detected by two-way ANOVA ($p < 0.001$) (Figure 4). These results may indicate that the effective doses of RT16 are not toxic to the cells.
3.3. The Effect of RT16 Fraction on Cell Cycle Progression

Treatment of the cells with RT16 resulted in significant reduction in cell viability. Therefore, it was needed to test the effect of RT16 on cell cycle progression. Cells were treated with different doses of RT16, 2.5, 5 and 10 µg/mL, or with 200 µM of etoposide for 4 h. Results indicated that exposure of the cells to RT16 significantly resulted in accumulation of the cells in the sub-G1 phase of the cell cycle (Figure 5). These results indicated that RT16 may induce apoptosis.
**Figure 5.** Analysis of cell cycle distribution. HPAF-II and PL45 cells were exposed to medium (control), RT16 (2.5, 5, 10 µg/mL), CS extract (10 µg/mL), or etoposide (200 µM) for 4 h. Cells were then harvested, fixed, and stained with PI and subjected to cell cycle analysis using FACS Calibur. The distribution and percentage of cells in the sub-G1 phase of the cell cycle are presented. Results presented are an average of at least three independent experiments, 3–5 repeats each (means ± SEM). Statistical significance was determined by one-way ANOVA followed by post hoc analysis, \( p < 0.001 \).

Each letter represents relations to a fellow cell line in the same treatment period.

### 3.4. The Effect of the Isolated Active Compound on Induction of Apoptosis

In order to confirm that the accumulation of cells in the sub-G1 phase of the cell cycle is a result of induction of apoptosis, PL45 and HPAF-II cells were stained with FITC-labeled annexin-V and PI and analyzed by flow cytometry, as described under “Section 2”. For both cell lines, treatment for 4 h yielded an increase in apoptotic cells. Exposure of PL45 and HPAF-II cells to 10 µg/mL of purified RT16 fraction resulted in 52% and 32% apoptotic cells, respectively. Exposure of the cells to etoposide (200 µM) resulted in 6% and 18.5% apoptotic cells in HPAF-II and PL45, respectively, (HPAF-II: \( p = 0.32 \) and PL45: \( p < 0.001 \)) (Figure 6).

For additional characterization of apoptotic cells, TUNEL assay was conducted, as described under “Section 2”. HPAF-II and PL45 cells were treated with purified RT16 fraction, CS extract (10 µg/mL), or etoposide (200 µM) for 4 h. Cells were labeled with TUNEL and DAPI and apoptotic cells were observed under fluorescent microscope. Cells treated with 10 µg/mL of the RT16 fraction presented typical apoptotic morphology, such as shrinkage of the cell and condensation of nuclear chromatin, as well as they exhibited the biochemical hallmark of apoptosis; internucleosomal DNA fragmentation in a more distinct manner than the CS extract- or the etoposide-treated cells (Figure 7).
Figure 6. Annexin-V/PI staining for apoptosis. HPAF-II and PL45 cells were exposed to either medium (control), RT16 (2.5, 5, 10 μg/mL), CS extract (10 μg/mL), or etoposide (200 μM) for 4 h, and then stained with Annexin V-FITC and propidium iodide. A total of 5 × 10^5 cells/mL were counted and collected for flow cytometry analysis. All results represent means ± SEM of three independent experiments. Statistical significance was determined by one-way ANOVA followed by post hoc analysis, *p* < 0.001. Each letter represents relations to fellow concentrations in the same cell line.

Figure 7. TUNEL and DAPI staining for apoptosis detection in HPAF-II and PL45 cells. A total of 3 × 10^4 cells were seeded on chamber slides (Nunc, Denmark). After 24 h, the cells were treated with RT16 or CS extract for 4 h at a concentration of 10 μg/mL. At the end of the treatment, the cells were stained with TUNEL (Roche Applied Science, Mannheim, Germany) and DAPI (Vector laboratories Inc., Burlingame, CA, USA) and analyzed under fluorescent microscopy (×200 magnification).
4. Discussion

Previously, we found that ethyl acetate culture liquid extract from *Cyathus striatus* (CS) inhibited cell growth and induced apoptosis of human pancreatic cancer cells in vitro and inhibited tumor growth in vivo [22,23]. Based on these results, we aimed to identify the structure of the active compound on the CS extract. Fractionation studies and chemical analysis indicated that fraction RT16 contains one compound that was characterized as striatal C with the formula of C$_{25}$H$_{34}$O$_{7}$. Moreover, we found that the purified RT16 fraction inhibited cell growth and induced apoptosis of cancer cells originated from human pancreatic cancer. In addition, the results indicated that effective doses of the RT16 fraction are not toxic to the cells, as well as the CS extract. Previously, we found that the CS extract effect is mediated by the induction of apoptosis via activation of both the intrinsic and extrinsic caspase pathways. Moreover, RNA-seq transcriptome analysis indicated that the CS extract may induce apoptosis via endoplasmic reticulum stress through the PERK/eIF2α/ATF4/CHOP pathway [23].

*Cyathus striatus* has proven to be a rich source of bioactive chemical compounds, as well as other medicinal mushrooms, that helps modulate the immune system, possess anti-cancer activity, and anti-oxidant properties [6]. It was reported that CS produces indolic substances, as well as a complex of diterpenoid antibiotic compounds, collectively known as cyathins [20,27]. Other study revealed the indole substances, known as striatins (A, B, and C), have antibiotic activity against *Fungi Imperfecti* and various Gram-positive and Gram-negative bacteria [21]. In addition, *Cyatus striatus* also produces sesquiterpene compounds called schizandronols [28]. It also contains the triterpene compounds glochidone, glochidionol, glochidiol and glochidiol diacetate, cyathic acid, striatic acid, cyathadonic acid, and epistriatic acid [29].

Epidemiological studies indicated that there is a correlation between cruciferous vegetable intake, vegetables that are rich in indole derivatives, and the development of cancer. Therefore, natural indole derivatives became very important compounds in drug-discovery development. Indoles represent a very important class of molecules that play a major role in cell biology and cancer research [30]. Previously, we found that indole derivatives—indole-3-carbinol (IC3) and 3,3′-diindolylmethan (DIM)—inhibited cell proliferation of human breast and prostate cancer cells in vitro [31,32]. Moreover, in vivo studies indicated that indole derivatives are not toxic, inhibit tumor growth, and have preventive effects against the development of prostate cancer in animal models [33,34].

Other studies indicated that indole derivatives represent anti-proliferative activities against hepatic and breast cancer cells. By studying the mechanism of action, it was reported that indole derivatives inhibit tubulin polymerization which leads to mitotic spindle formation disruption, cell cycle arrest in the G2/M phase, and induction of apoptosis [35]. Moreover, it was indicated that I3C and DIM modulate expression of a number of miRNAs. The number of target genes is important in the regulation of the cell cycle and apoptosis [36].

Triterpenes have numerous biological activities such as anti-cancer, anti-inflammatory, anti-oxidative, anti-viral, anti-bacterial, and anti-fungal properties [37]. Moreover, it was found that edible mushrooms play a role in preventing neurodegenerative diseases, such as Parkinson’s and Alzheimer’s. The mechanisms of action include reducing oxidative stress, neuroinflammation, and modulation of acetylcholinesterase activity [6]. Another study examined four mushrooms (*Fomitopsis pinicola*, *Hericium erinaceus*, *Inonotus obliquus*, and *Trametes versicolor*), commonly used in Asian and Far Eastern folk medicine, which targeted several biological processes relevant to cancer treatment [7]. In addition, it was reported that production of the nutritionally and medically rich oyster mushroom *Pleurotus Florida* induces apoptosis in human colon cancer cells [8].

In the present study, we identified striatal C in CS extract that exhibited anti-cancer properties. Striatal C induced apoptosis in human pancreatic cancer cells; therefore, striatal C can be added to the list of anti-cancer compounds in CS.

Pancreatic cancer is a disease with very poor prognosis and remains one of the deadliest cancer types world-wide [38]. According to the Global Cancer Observatory (GLOBO-
CAN), an estimated of 495,773 patients were newly diagnosed with pancreatic cancer worldwide in 2020 [38]. Therefore, as a malignant tumor with poor prognosis, improving the overall survival rate of pancreatic cancer patients is still a major challenge. Most patients lack sensitivity to most standard therapies, therefore, there is a need to develop new therapeutic strategies.

The anti-tumor activities of striatal C that was purified from the CS extract, as well as the proven utility of its anti-mitotic compounds against cancer cells, make striatal C an interesting compound with potential chemotherapeutic effects that may merit further research.

5. Conclusions

Ethyl acetate extracts from Cyathus striatus media inhibited cell growth of human pancreatic cancer cells and induced apoptosis through extrinsic and intrinsic pathways. Moreover, the CS extract inhibited tumor growth of pancreatic cells in animal models. The present study identified the chemical structure of striatal C, the main active compound in the CS extract. The results indicated for the first time that striatal C induced apoptosis in human pancreatic cancer cells. Further studies should be designed in order to clarify striatal C’s molecular mechanism of action. In addition, further studies are needed in order to develop a method for the synthesis of striatal C in order to use it in clinical studies for the treatment of cancer.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules27092746/s1, Figure S1: (A) HPLC chromatogram of the mushroom ethyl acetate crude extract (2 mg/mL). (B) The purified active compound (2 mg/mL) obtained at 210 nm using photodiode array detector; Figure S2: 1H-NMR for the compound appeared at 16 min. in the HPLC chromatogram; Figure S3: 13C-NMR (zgig) for the compound appeared at 16 min. in the HPLC chromatogram; Figure S4: 13C-NMR (dept135) for the compound appeared at 16 min. in the HPLC chromatogram; Figure S5: Two dimensional 1H-1H NMR (cosygpqf) for the compound appeared at 16 min. in the HPLC chromatogram; Figure S6: Two dimensional 1H-13C NMR (HSQC) for the compound appeared at 16 min. in the HPLC chromatogram; Figure S7: Two dimensional 1H-13C NMR (HMBC) for the compound appeared at 16 min. in the HPLC chromatogram.

Author Contributions: Supervision and design of the study, F.F. and S.W.; writing the manuscript, S.K. and F.F.; fractionation studies, identification of the structure of the active compound, S.K. and J.V.; bioactivity of the fractions and isolated compound in cancer cells, L.S. and E.E. All authors have read and agreed to the published version of the manuscript.

Funding: The project was funded by Carmel-University of Haifa-Economic Corporation Ltd., Haifa, Israel. Grant # 100006015.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Acknowledgments: The authors would like to thank Carmel-University of Haifa-Economic Corporation Ltd., Haifa, Israel, for supporting this project.

Conflicts of Interest: All authors are disclosing any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations.

References

1. Tan, G.; Gyllenhaal, C.; Soejarto, D.D. Biodiversity as a source of anticancer drugs. Curr. Drug Targets 2006, 7, 265–277. [CrossRef] [PubMed]
2. Sullivan, R.; Smith, J.; Rowan, N.J. Medicinal mushrooms and cancer therapy: Translating a traditional practice into Western medicine. Perspect. Biol. Med. 2006, 49, 159–170. [CrossRef] [PubMed]
3. Wasser, S.P. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. <i>Appl. Microbiol. Biotechnol. 2002, 60, 258–274. [CrossRef] [PubMed]</i>

4. Wasser, S.; Akavia, E. Regulatory issues of mushrooms as functional foods and dietary supplements: Safety and efficacy. In <i>Mushrooms as Functional Foods</i>; Wiley: New York, NY, USA, 2008.

5. Wasser, S.P. Medicinal mushroom science: History, current status, future trends, and unsolved problems. <i>Int. J. Med. Mushrooms 2010, 12, 1–16. [CrossRef]</i>

6. Rai, S.N.; Mishra, D.; Singh, P.; Vamanu, E.; Singh, M. Therapeutic applications of mushrooms and their biomolecules along with a glimpse of in silico approach in neurodegenerative diseases. <i>Biomed. Pharmacother. 2021, 137, 11377. [CrossRef]</i>

7. Blagodatski, A.; Yatsunskaya, M.; Mikhailova, V.; Tiasto, V.; Kagansky, A.; Katanaev, V.L. Medicinal mushrooms as an attractive new source of natural compounds for future cancer therapy. <i>OncoTargets 2018, 9, 29259–29274. [CrossRef]</i>

8. Chaturvedi, V.K.; Yadav, N.; Rai, N.K.; Bohara, R.A.; Rai, S.N.; Aleya, L.; Singh, M.P. Two birds with one stone: Oyster mushroom mediated bime Tallic Au-Pt nanoparticles for agro-waste management and anticancer activity. <i>Environ. Sci. Pollut. Res. 2021, 28, 13761–13775. [CrossRef]</i>

9. Chaturvedi, V.K.; Rai, S.N.; Tabassum, N.; Yadav, N.; Singh, V.; Bohara, R.A.; Singh, M.P. Rapid eco-friendly synthesis, characterization, and cytotoxic study of trimetallic stable nanomedicine: A potential material for biomedical applications. <i>Biochem. Biophys. Rep. 2020, 24, 100812. [CrossRef] [PubMed]</i>

10. Singh, M.P.; Rai, S.N.; Dubey, S.K.; Pandey, A.T.; Tabassum, N.; Chaturvedi, V.K.; Singh, N.B. Biomolecules of mushroom: A recipe of human wellness. <i>Crit. Rev. Biotechnol. 2021, 1–18. [CrossRef] [PubMed]</i>

11. Mizuno, T. The extraction and development of antitumor-active polysaccharides from medicinal mushrooms in Japan. <i>Int. J. Med. Mushrooms 1999, 1, 9–29. [CrossRef] [PubMed]</i>

12. Tomatis, L.; Melnick, R.L.; Haseman, J.; Barrett, J.C.; Huff, J. Alleged ‘misconceptions’ distort perceptions of environmental cancer risks. <i>FASEB J. 2001, 15, 195–203. [CrossRef] [PubMed]</i>

13. Chang, S.; Wasser, S.P. The role of culinary-medicinal polysaccharides on human welfare with a pyramidal model for human health. <i>Int. J. Med. Mushrooms 2012, 14, 95–134. [CrossRef] [PubMed]</i>

14. Wasser, S.; Weis, A.L. Medicinal properties of substances occurring in higher basidiomycetes mushrooms: Current perspectives. <i>Int. J. Med. Mushrooms 1999, 1, 31–62. [CrossRef] [PubMed]</i>

15. Zaidman, B.-Z.; Yassin, M.; Mahajna, J.; Wasser, S.P. Medicinal mushroom modulators of molecular targets as cancer therapeutics. <i>Appl. Microbiol. Biotechnol. 2005, 67, 453–468. [CrossRef]</i>

16. Schneider, G.; Saur, D.; Schmid, R.M. Pancreatic cancer—Molecular alterations. <i>Chin.-Ger. J. Clin. Oncol. 2007, 6, 102–106. [CrossRef]</i>

17. Maitra, A.; Hruban, R.H. Pancreatic Cancer. <i>Annu. Rev. Pathol. 2008, 3, 157–188. [CrossRef] [PubMed]</i>

18. Welsch, T.; Kleeff, J.; Friess, H. Molecular pathogenesis of pancreatic cancer: Advances and challenges. <i>Curr. Mol. Med. 2007, 7, 504–521. [CrossRef]</i>

19. Hezel, A.F.; Kimmelman, A.C.; Stanger, B.Z.; Bardeesy, N.; DePinho, R.A. Genetics and biology of pancreatic ductal adenocarcinoma. <i>Genes Dev. 2006, 20, 1218–1249. [CrossRef] [PubMed]</i>

20. Allbutt, A.D.; Ayer, W.A.; Brodie, H.J.; Johri, B.N.; Taube, H. Cyathin, a new antibiotic complex produced by Cyathus helenae. <i>Can. J. Microbiol. 1971, 17, 1401–1407. [CrossRef] [PubMed]</i>

21. Sharvit, L.; Bar-Shalom, R.; Azzam, N.; Yechiel, Y.; Wasser, S.; Fares, F. <i>Cyathus striatus</i> Extract Induces Apoptosis in Human Pancreatic Cancer Cells and Inhibits Xenograft Tumor Growth In Vivo. <i>Cancers 2021, 13, 2017. [CrossRef]</i>

22. Sharvit, L.; Wasser, S.; Fares, F. The effect of culture liquid ethyl acetate mycelium extracts of medicinal mushrooms on the viability of human pancreatic cancer cells. <i>Int. J. Med. Mushrooms 2012, 14, 169–179. [CrossRef] [PubMed]</i>

23. Yassin, M.; Mahajna, J.A. Submerged cultured mycelium extracts of higher Basidiomycetes mushrooms selectively inhibit proliferation and induce differentiation of K562 human chronic myelogenous leukemia cells. <i>Int. J. Med. Mushrooms 2003, 5, 1–16. [CrossRef]</i>

24. Khan, I.A.; Alam, S.S.; Jabbar, A. Standardization of Medium. Available online: https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Khan+I.A%2C+Alam+S.S%2C+Jabbar+A.+Standardization+of+medium+for+the+production+of+maximum+phytotoxic+activity+by+Fusarium+oxysporum+f.+sp.+ciceris.+Pak+J+Biol+Sci.+2001%3B4%281%29%3A1374-1376.&btnG= (accessed on 6 March 2022).

25. Moran, J.; Schnellmann, R.G. A Rapid β-NADH-Linked Fluorescence Assay for Lactate Dehydrogenase in Cellular Death. <i>J. Pharmacol. Toxicol. Methods 1996, 36, 41–44. [CrossRef] [PubMed]</i>

26. Johri, B.N.; Brodie, H.J. Extracellular Production of Indolics by the Fungus Cyathus. <i>Mycologia 1971, 63, 736–744. [CrossRef] [PubMed]</i>

27. Ayer, W.A.; Refstrup, T. Metabolites of bird’s nest fungi. Part 18. new oxygenated cadinane derivatives from <i>Cyathus striatus</i>. <i>Tetrahedron 1982, 38, 1409–1412. [CrossRef]</i>

28. Ayer, W.A.; Flanagan, R.J.; Refstrup, T. Metabolites of bird’s nest fungi-19. New triterpenoid carboxylic acids from <i>Cyathus striatus</i> and <i>Cyathus pygmaeus</i>. <i>Tetrahedron 1984, 40, 2069–2082. [CrossRef]</i>

29. Kaushik, N.K.; Kaushik, N.; Attril, P.; Kumar, N.; Kim, C.H.; Verma, A.K.; Choi, E.H. Biomedical Importance of Indoles. <i>Molecules 2013, 18, 6620–6662. [CrossRef]</i>
30. Nachshon-Kedmi, M.; Yannai, S.; Fares, F.A. Induction of apoptosis in human prostate cancer cell line, PC3, by 3,3′-diindolylmethane through the mitochondrial pathway. *Br. J. Cancer* 2004, 91, 1358–1363. [CrossRef]

31. Fares, F.A.; Ge, X.; Yannai, S.; Rennert, G. Dietary indole derivatives induce apoptosis in human breast cancer cells. *Adv. Exp. Med. Biol.* 1998, 451, 153–157. [CrossRef]

32. Fares, F.; Azzam, N.; Appel, B.; Fares, B.; Stein, A. The potential efficacy of 3,3′-diindolylmethane in prevention of prostate cancer development. *Eur. J. Cancer Prev.* 2010, 19, 199–203. [CrossRef]

33. Nachshon-Kedmi, M.; Fares, F.A.; Yannai, S. Therapeutic Activity of 3,3′-Diindolylmethane on Prostate Cancer in an in vivo Model. *Prostate* 2004, 61, 153–160. [CrossRef] [PubMed]

34. El-Sayed, N.F.; El-Hussieny, M.; Ewies, E.F.; El Shehry, M.F.; Awad, H.M.; Fouad, M.A. Design, Synthesis, Biological Evaluation, and Molecular Docking of New Benzofuran and Indole Derivatives as Tubulin Polymerization Inhibitors. *Drug Dev. Res.* 2021. [CrossRef] [PubMed]

35. Williams, D.E. Indoles Derived From Glucobrassicin: Cancer Chemoprevention by Indole-3-Carbinol and 3,3′-Diindolylmethane. *Front. Nutr.* 2021, 8, 691. [CrossRef] [PubMed]

36. Chudzik, M.; Korzonek-Szacheta, I.; Król, W. Triterpenes as Potentially Cytotoxic Compounds. *Molecules* 2015, 20, 1610–1625. [CrossRef]

37. Ilic, M.; Ilic, I. Epidemiology of pancreatic cancer. *World J. Gastroenterol.* 2016, 22, 9694–9705. [CrossRef]

38. Cai, J.; Chen, H.; Lu, M.; Zhang, Y.; Lu, B.; You, L.; Zhao, Y. Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis. *Cancer Lett.* 2021, 520, 1–11. [CrossRef]